• Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise

Log in

Start free trial
G2 Intelligence
  • Reports
    • Lab Industry Advisor
      • Essentials Reports
      • Premium Reports
      • Elite Reports
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Articles
    • Lab Industry Advisor
    • Clinical Diagnostics Insider
    • Archive
      • Diagnostic Testing and Emerging Technologies
      • Lab Compliance Advisor
      • Laboratory Industry Report
      • National Lab Reporter
  • Webinars
  • Store
FDA Watch: Agency Takes Steps to Downgrade Some Nucleic Acid-Based Tests to Class II

FDA Watch: Agency Takes Steps to Downgrade Some Nucleic Acid-Based Tests to Class II

by Ron Shinkman | Dec 29, 2025 | Essential, FDA-lca, FDA-lir, FDA-nir, Lab Industry Advisor

The change is expected to dramatically cut the costs of developing new tests

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
FDA Watch: CND Life Sciences Wins Breakthrough Device Designation for Skin-Based Neurodegenerative Test

FDA Watch: CND Life Sciences Wins Breakthrough Device Designation for Skin-Based Neurodegenerative Test

by Ron Shinkman | Nov 26, 2025 | Essential, FDA-lca, FDA-lir, FDA-nir, Lab Industry Advisor

The Syn-One assay can diagnose multiple conditions without needing a lumbar puncture

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
Chevron Doctrine’s Dismissal Has Yet to Upend Regulatory Environment

Chevron Doctrine’s Dismissal Has Yet to Upend Regulatory Environment

by Oscelle Boye, MBiomed | Oct 26, 2025 | FDA-lca, FDA-lir, FDA-nir, Lab Industry Advisor, LDTs-lir, Legislation-lca, Legislation-lir, Legislation-nir

However, clinical laboratories may have more say in future laws and guidance thanks to 2024 decision

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
FDA Watch: Mass Spectrometry Test Receives First Moderate Complexity Designation

FDA Watch: Mass Spectrometry Test Receives First Moderate Complexity Designation

by Ron Shinkman | Oct 24, 2025 | CLIA-lca, CLIA-nir, Essential, FDA-lca, FDA-lir, FDA-nir, Lab Industry Advisor

Roche’s vitamin D assay includes internal quality controls that allowed it to obtain the CLIA designation

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
National Lab Companies Move Quickly to Market Fujirebio’s Lumipulse for Earlier Alzheimer’s Detection

National Lab Companies Move Quickly to Market Fujirebio’s Lumipulse for Earlier Alzheimer’s Detection

by Ron Shinkman | Sep 26, 2025 | Clinical Diagnostics Insider, Emerging Tests-dtet, FDA-dtet

The new blood-based assay avoids painful lumbar punctures and may quicken Alzheimer’s diagnoses

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here
« Older Entries

Log In

Join Now | Lost Password?
  • Follow
  • Follow
  • Homepage
  • FAQ
  • About Us
  • G2 Intelligence Team
  • Contact Us
  • Privacy Policy
  • Terms
  • Advertise
Copyright © 2026 G2Intelligence.com